YOUR FRIENDS' ACTIVITY

    Takepart.com

    Once-a-Day HIV Quad Drug Stribild Gets FDA Approval

    Add one more medication to the HIV treatment arsenal: The quad-drug Stribild, geared specifically for people who haven’t yet been treated for the infection, just got the OK from the Food and Drug Administration.

    Stribild, from California-based Gilead Sciences, combines four drugs into a once-a-day pill: elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate. The first two drugs are new, according to an FDA release. Elvitegravir is an integrase inhibitor and stops the HIV virus from replicating by preventing HIV DNA from going into healthy cells. Cobicistat enhances the effects of elvitegravir.

    Emtricitabine and tenofovir disoproxil fumarate also stop viral replication and are better known as Truvada. Truvada, which has been used to treat HIV, was also approved in July by the FDA as a preventive treatment for high-risk people.

    MORE: Zimbabwe Lawmakers Get Circumcised to Fight HIV

    Stribild drug is seen as a welcome alternative to “cocktail” drugs, or multiple drug regimens.

    “Through continued research and drug development, treatment for those infected with HIV has evolved from multi-pill regimens to single-pill regimens,” Dr. Edward Cox said in a news release. Cox, director of the Office of Antimicrobial Products in the FDA’s Center for Drug Evaluation and Research, added, “New combination HIV drugs like Stribild help simplify treatment regimens.”

    Last month the FDA also approved an over-the-counter at-home test for HIV that has a 92 percent to 99 percent accuracy rate and is geared to people who want privacy and quick results.

    In two double-blind trials on Stribild, between 88 percent and 90 percent of patients had an unnoticeable amount of HIV in their blood after about a year. The results were slightly better than other existing HIV medications.

    MORE: Quick Study: Could Results of Bone Marrow Transplants Hold Secrets to an AIDS Cure?

    But Stribild does not come without warnings and side effects. A boxed warning advises patients that the drug carries the risk of severe liver problems as well as a build-up of lactic acid in the blood.

    Side effects noticed in clinical trials included nausea and diarrhea, plus lower bone mineral density, kidney problems and changes in the immune system.

    Do you think advances in HIV medication are going in the right direction? Let us know in the comments.

    Related Stories on TakePart:

    • From AIDS Relief to Education Reform

    • AIDS Conference: Thousands Gather to Talk Cures, Treatments and Funding for the Global Epidemic

    • A Drop in Circumcision Rates Could Mean Billions in Healthcare Costs


    Jeannine Stein, a California native, wrote about health for the Los Angeles Times. In her pursuit of a healthy lifestyle she has taken countless fitness classes, hiked in Nepal, and has gotten in a boxing ring. Email Jeannine | TakePart.com

    Loading...
    • Cycling-Road-Giro d'Italia points classification after stage 18

      May 23 (Infostrada Sports) - Points Classification Giro d'Italia after Stage 18 on Thursday 1. Mark Cavendish (Britain / Omega Pharma - Quick-Step) 113 2. Cadel Evans (Australia / BMC Racing) 109 3. Vincenzo Nibali (Italy / Astana) 103 4. Carlos Betancur (Colombia / AG2R) 94 5. Mauro Santambrogio (Italy / Vini Fantini) 89 6. Giovanni Visconti (Italy / Movistar) 86 7. Rigoberto Uran (Colombia / Team Sky) 86 8. Elia Viviani (Italy / Cannondale) 72 9. Ramunas Navardauskas (Lithuania / Garmin) 65 10. Giacomo Nizzolo (Italy / RadioShack) 61

    • Dog Found Standing Guard Over a Tornado Victim Reunited With Her Owner

      There's a happy ending to the story of a dog, found alive in the rubble after a massive tornado devastated Moore, Oklahoma: she's been reunited with her owner.

    • Motor racing-Pirelli warn they could quit F1

      By Alan Baldwin MONACO, May 23 (Reuters) - Formula One tyre supplier Pirelli warned teams on Thursday that they will quit the sport at the end of the season if a new contract from 2014 is not agreed soon. Motorsport director Paul Hembery did not hide his impatience when he told reporters at the Monaco Grand Prix that time was running out for the Italian company to design and test tyres suitable for radically different 2014 regulations. "Apparently on Sept. 1 we are meant to tell them (the teams) everything that they need to know for the tyres for next season. ...

    • Trayvon Martin texts, photos: Might they change Zimmerman trial?

      Ultimately, many of the photos and cellphone records of Trayvon Martin released online Thursday by George Zimmerman’s defense attorneys – indicating that the slain teenager smoked marijuana, got into fights at school, and had an interest in, and perhaps access to, guns – may be ruled inadmissible in court. But they are already making the rounds in the court of public opinion, which can influence everything from fundraising efforts to the mind-set of potential jurors in Mr. Zimmerman's murder trial.

    • Stockholm is burning: Why the Swedish riots bode ill for Europe

      Rampaging immigrant youths have upended the country's reputation as a prosperous refuge

    • Michelle Obama vacation: Will critics slam this trip too?

      Michelle Obama and daughters Sasha and Malia are looking at an extended vacation on Martha’s Vineyard this summer, according to a report in The Boston Globe. The Globe might have something here – it’s almost a local Vineyard paper, after all.

    • Distraught mom becomes face of Oklahoma storm

      MOORE, Okla. (AP) — A massive tornado was carving its way through town. There was no time to hesitate. LaTisha Garcia had to get to her children.

    • Woman accused of contaminating daughter's IV tubes

      TUCSON, Ariz. (AP) — A prosecutor says a woman on trial in Tucson contaminated her hospitalized infant daughter's intravenous lines in an attempt to get attention from the girl's father.

    Loading...

    Follow Yahoo! News